190 related articles for article (PubMed ID: 8754494)
21. Expression of pS2 protein in breast cancer.
Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ
Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of pS2 mRNA in breast cancer.
Wysocki SJ; Iacopetta BJ; Ingram DM
Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621
[TBL] [Abstract][Full Text] [Related]
24. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.
van Agthoven T; van Agthoven TL; Dekker A; Foekens JA; Dorssers LC
Mol Endocrinol; 1994 Nov; 8(11):1474-83. PubMed ID: 7533260
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
26. Up-regulation of pS2 expression during the development of adenocarcinomas but not squamous cell carcinomas of the uterine cervix, independently of expression of c-jun or oestrogen and progesterone receptors.
Saegusa M; Hashimura M; Hara A; Okayasu I
J Pathol; 2000 Apr; 190(5):554-63. PubMed ID: 10727981
[TBL] [Abstract][Full Text] [Related]
27. Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer.
Corte MD; González LO; Lamelas ML; Alvarez A; Junquera S; Allende MT; García-Muñiz JL; Argüelles J; Vizoso FJ
Breast Cancer Res Treat; 2006 Jun; 97(3):329-37. PubMed ID: 16791488
[TBL] [Abstract][Full Text] [Related]
28. Immunoradiometric assay of pS2 protein in breast cancer cytosols.
Goussard J; Lechevrel C; Roussel G; Cren H; Bera O; Sala M
Clin Chem; 1991 Oct; 37(10 Pt 1):1759-62. PubMed ID: 1914181
[TBL] [Abstract][Full Text] [Related]
29. Relation of epidermal growth factor receptor and estrogen receptor-independent pS2 protein to the malignant transformation of mucinous cystic neoplasms of the pancreas.
Kirby RE; Lewandrowski KB; Southern JF; Compton CC; Warshaw AL
Arch Surg; 1995 Jan; 130(1):69-72. PubMed ID: 7802579
[TBL] [Abstract][Full Text] [Related]
30. [pS2 protein and breast cancer].
Torre EA; Fulco RA
Minerva Ginecol; 1995 Dec; 47(12):553-6. PubMed ID: 8720977
[TBL] [Abstract][Full Text] [Related]
31. Expression of an estrogen-induced breast cancer-associated protein (pS2) in benign and malignant human ovarian cysts.
Dante R; Ribieras S; Baldassini S; Martin V; Benzerara O; Bouteille C; Brémond A; Frappart L; Rio MC; Lasne Y
Lab Invest; 1994 Aug; 71(2):188-92. PubMed ID: 8078298
[TBL] [Abstract][Full Text] [Related]
32. Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7).
Kida N; Yoshimura T; Mori K; Hayashi K
Cancer Res; 1989 Jul; 49(13):3494-8. PubMed ID: 2731170
[TBL] [Abstract][Full Text] [Related]
33. pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer.
Jansen RL; Hupperets PS; Arends JW; Joosten-Achjanie SR; Volovics A; Hillen HF; Schouten HC
Anticancer Res; 1998; 18(1B):577-82. PubMed ID: 9568180
[TBL] [Abstract][Full Text] [Related]
34. pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.
Correale M; Abbate I; Paradiso A; Schittulli F; Dragone CD; Tedone T; Gargano G; Catino AM; Musci MD; De Lena M
Cell Biophys; 1993; 22(1-3):101-10. PubMed ID: 7889536
[TBL] [Abstract][Full Text] [Related]
35. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
36. [Estrogen receptor studies in breast cancer based on histological material. Correlation with results from needle biopsy aspirates and pS2 protein determination].
Sauer T; Naess O
Tidsskr Nor Laegeforen; 1995 Sep; 115(23):2881-3. PubMed ID: 7570508
[TBL] [Abstract][Full Text] [Related]
37. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
[TBL] [Abstract][Full Text] [Related]
38. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
[TBL] [Abstract][Full Text] [Related]
39. Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors.
Hanby AM; McKee P; Jeffery M; Grayson W; Dublin E; Poulsom R; Maguire B
Am J Surg Pathol; 1998 Sep; 22(9):1125-31. PubMed ID: 9737246
[TBL] [Abstract][Full Text] [Related]
40. Estrogen and progesterone receptors and pS2 and ERD5 antigens in gastric carcinomas from the European population.
Chaubert P; Bouzourene H; Saraga E
Mod Pathol; 1996 Mar; 9(3):189-93. PubMed ID: 8685212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
